We are live on ! Find out more
TRDA icon

Entrada Therapeutics
TRDA

120 hedge funds and large institutions have $343M invested in Entrada Therapeutics in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

47% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 32

28% more capital invested

Capital invested by funds: $269M → $343M (+$74.6M)

5% more funds holding

Funds holding: 114 → 120 (+6)

2.62% more ownership

Funds ownership: 68.47% → 71.09% (+2.6%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
120
Holders Change
+6
Holders Change %
+5.26%
% of All Funds
1.48%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
20
Increased
47
Reduced
32
Closed
13
Calls
$292K
Puts
–
Net Calls
+$292K
Net Calls Change
+$176K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.42M
2
LP
Longaeva Partners
Illinois
+$2.35M
3
TCM
TCG Crossover Management
California
+$2.28M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.28M
5
LCM
Lynx1 Capital Management
Puerto Rico
+$1.83M

Top Sellers

Rank Fund Capital Flow
1
RA
Royce & Associates
New York
-$1.45M
2
AG
Algert Global
California
-$1.32M
3
SFM
Sphera Funds Management
Israel
-$1.14M
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$1.01M
5
Morgan Stanley
Morgan Stanley
New York
-$964K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$64M – – –
5VM
2
5AM Venture Management
California
$51.2M – – –
BlackRock
3
BlackRock
New York
$29.8M +$2.42M +211,533 +10%
TCM
4
TCG Crossover Management
California
$28.9M +$2.28M +199,108 +10%
MC
5
Merck & Co
New Jersey
$22M – – –
VCM
6
Vanguard Capital Management
Pennsylvania
$15.9M +$14.4M +1,256,013 New
Wellington Management Group
7
Wellington Management Group
Massachusetts
$13.1M -$114K -9,976 -1%
SG
8
StepStone Group
California
$9.61M – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$8.42M +$314K +27,400 +4%
State Street
10
State Street
Massachusetts
$6.74M +$287K +25,009 +5%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$6.64M +$2.28M +198,620 +61%
Millennium Management
12
Millennium Management
New York
$6.55M +$248K +21,661 +4%
JHC
13
Jones Hill Capital
New York
$4.72M +$4.29M +374,010 New
Jacobs Levy Equity Management
14
Jacobs Levy Equity Management
New Jersey
$4.21M -$331K -28,872 -8%
Acadian Asset Management
15
Acadian Asset Management
Massachusetts
$4.2M +$256K +22,336 +7%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$4.09M +$586K +51,093 +19%
Northern Trust
17
Northern Trust
Illinois
$2.97M +$99.6K +8,691 +4%
VPM
18
Vanguard Portfolio Management
Pennsylvania
$2.78M +$2.53M +220,494 New
WP
19
Woodline Partners
California
$2.73M +$847K +73,867 +52%
Citadel Advisors
20
Citadel Advisors
Florida
$2.71M -$891K -77,752 -27%
Charles Schwab
21
Charles Schwab
California
$2.71M -$74.7K -6,518 -3%
Goldman Sachs
22
Goldman Sachs
New York
$2.69M +$87.2K +7,607 +4%
LCM
23
Lynx1 Capital Management
Puerto Rico
$2.67M +$1.83M +160,000 +310%
LP
24
Longaeva Partners
Illinois
$2.59M +$2.35M +204,978 New
Renaissance Technologies
25
Renaissance Technologies
New York
$2.55M -$579K -50,551 -20%
1
2 3 4 5

TRDA Hedge Fund Activity: Q1 2026 in Review

120 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q1 2026, worth a combined $343M — up 28% from $269M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new TRDA positions and 13 closed out — a net gain of 7 holders — while 47 added to existing stakes and 32 trimmed.

The largest buyer was BlackRock, adding an estimated $2.42M. The largest seller was Royce & Associates, cutting an estimated $1.45M.

  • 120 institutional investors held Entrada Therapeutics (TRDA) as of Q1 2026, up from 114 in Q4 2025.
  • Funds reported $343M of Entrada Therapeutics stock for Q1 2026, up 28% quarter-over-quarter.
  • 20 funds opened new Entrada Therapeutics positions in Q1 2026 and 13 closed out, a net change of +7 holders.
  • The largest Entrada Therapeutics buyer in Q1 2026 was BlackRock, an estimated $2.42M added.
  • The largest Entrada Therapeutics seller in Q1 2026 was Royce & Associates, an estimated $1.45M sold.

Based on aggregated 13F filings for Q1 2026.